{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:14:08Z","timestamp":1789121648261,"version":"build-2803163510"},"reference-count":27,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Visual evoked potentials (VEPs) are established tools for detecting optic pathway involvement in multiple sclerosis (MS); however, the distinct clinical significance of longitudinal changes in latency and amplitude remains unclear. This exploratory study aimed to evaluate the clinical utility of serial VEP assessments in patients with relapsing\u2013remitting MS (RRMS) by examining the associations between temporal changes in latency and amplitude and concurrent markers of disease activity and disability. Materials and Methods: We retrospectively analyzed 83 patients with RRMS from three centers who underwent at least two pattern-reversal VEP assessments \u2265 1 year apart. Patients with recent optic neuritis were excluded. Longitudinal changes in VEP latency and amplitude were evaluated in relation to relapse activity during the same inter-assessment interval, baseline MRI and CSF findings, and disability assessed by the Expanded Disability Status Scale (EDSS). Sensitivity analyses were stratified and adjusted for disease-modifying therapy (DMT) efficacy tier, and progression independent of relapse activity (PIRA) was examined using a formal definition. Results: Over a median follow-up of 2 years, 43.4% of patients developed P100 latency prolongation, which was independently associated with a higher annualized relapse rate during the same interval (odds ratio [OR] 2.91, p = 0.005; area under the curve (AUC) 0.72 for concurrent on-study relapse activity), an association that persisted after adjustment for DMT efficacy tier, but not with disability worsening. In contrast, 56.6% of patients exhibited amplitude reduction, which was associated with greater disability accumulation at the group level, with higher EDSS scores at follow-up despite similar baseline values (p &lt; 0.05); the corresponding inverse correlation between amplitude decline and EDSS change was only nominally significant (\u03c1 = \u22120.231, p = 0.036), did not survive correction for multiple comparisons, and was attenuated after adjustment for baseline EDSS. Formally defined PIRA events were rare (n = 3), precluding inference. Baseline magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) findings differed in the latency group, with fewer MRI lesions and a lower immunoglobulin G (IgG) index, whereas no corresponding differences were observed in the amplitude group. Conclusions: In this exploratory cohort, longitudinal prolongation of VEP latency was associated with concurrent relapse activity, whereas amplitude decline showed a weaker, group-level association with disability. These findings are consistent with, but do not demonstrate, distinct inflammatory and neurodegenerative substrates, and warrant prospective validation before serial VEP monitoring can inform individualized management in MS.<\/jats:p>","DOI":"10.3390\/medicina62091750","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:17:42Z","timestamp":1789114662000},"page":"1750","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Visual Evoked Potential Changes Show Distinct Associations with Relapse Activity and Disability in Relapsing\u2013Remitting Multiple Sclerosis: A Multicenter Retrospective Cohort Study"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4511-133X","authenticated-orcid":false,"given":"Samet","family":"\u00d6ncel","sequence":"first","affiliation":[{"name":"Department of Neurology, Sakarya Training and Research Hospital, 54100 Sakarya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3858-0306","authenticated-orcid":false,"given":"Meral","family":"Sefero\u011flu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Bursa Y\u00fcksek \u0130htisas Training and Research Hospital, 16310 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"\u00d6merhoca","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ba\u011fc\u0131lar Training and Research Hospital, 34200 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-4872","authenticated-orcid":false,"given":"Semanur","family":"Aksu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sakarya Training and Research Hospital, 54100 Sakarya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ertu\u011frul","family":"\u00c7\u0131nar","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ba\u011fc\u0131lar Training and Research Hospital, 34200 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"K\u0131l\u0131\u00e7aslan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Bursa Y\u00fcksek \u0130htisas Training and Research Hospital, 16310 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9747-5285","authenticated-orcid":false,"given":"Abdulkadir","family":"Tun\u00e7","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Sakarya University, 54100 Sakarya, Turkey"},{"name":"Bloocell Health Technologies Industry and Trade Joint Stock Company, 54580 Sakarya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nil\u00fcfer Kale","family":"\u0130\u00e7en","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ba\u011fc\u0131lar Training and Research Hospital, 34200 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"ref_1","first-page":"151","article-title":"Optic neuritis, the most common initial presenting manifestation of multiple sclerosis in northern Iran","volume":"6","author":"Hojjati","year":"2015","journal-title":"Casp. J. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1474-4422(05)70071-5","article-title":"Clinically isolated syndromes suggestive of multiple sclerosis, part I: Natural history, pathogenesis, diagnosis, and prognosis","volume":"4","author":"Miller","year":"2005","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Vecchio, D., Barbero, P., Galli, G., Virgilio, E., Naldi, P., Comi, C., and Cantello, R. (2023). Prognostic Role of Visual Evoked Potentials in Non-Neuritic Eyes at Multiple Sclerosis Diagnosis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12062382"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S1474-4422(16)00068-5","article-title":"Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: A cohort study","volume":"15","author":"Arnow","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/ene.13404","article-title":"Progression of retinal ganglion cell loss in multiple sclerosis is associated with new lesions in the optic radiations","volume":"24","author":"Klistorner","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e200092","DOI":"10.1212\/NXI.0000000000200092","article-title":"Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort","volume":"10","author":"Oertel","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Guerrieri, S., Comi, G., and Leocani, L. (2021). Optical coherence tomography and visual evoked potentials as prognostic and monitoring tools in progressive multiple sclerosis. Front. Neurosci., 15.","DOI":"10.3389\/fnins.2021.692599"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10633-016-9553-y","article-title":"ISCEV standard for clinical visual evoked potentials: (2016 update)","volume":"133","author":"Odom","year":"2016","journal-title":"Doc. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/WNO.0000000000000704","article-title":"Visual evoked potentials as a biomarker in multiple sclerosis and associated optic neuritis","volume":"38","author":"Leocani","year":"2018","journal-title":"J. Neuroophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/jnnp.2005.086280","article-title":"Multimodal evoked potentials to assess the evolution of multiple sclerosis: A longitudinal study","volume":"77","author":"Leocani","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ana.21474","article-title":"Axonal loss and myelin in early ON loss in postacute optic neuritis","volume":"64","author":"Klistorner","year":"2008","journal-title":"Ann. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1474-4422(25)00275-3","article-title":"The use of optical coherence tomography and visual evoked potentials in the 2024 McDonald diagnostic criteria for multiple sclerosis","volume":"24","author":"Saidha","year":"2025","journal-title":"Lancet Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"104116","DOI":"10.1016\/j.msard.2022.104116","article-title":"Individual differences in visual evoked potential latency are associated with variance in brain tissue volume in people with multiple sclerosis: An analysis of brain function-structure correlates","volume":"68","author":"Covey","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Miletic-Drakulic, S., Miloradovic, I., Jankovic, V., Azanjac-Arsic, A., and Lazarevic, S. (2022). VEP Score of a Left Eye Had Predictive Values for Achieving NEDA-3 over Ten Years in Patients with Multiple Sclerosis. Sensors, 22.","DOI":"10.3390\/s22228849"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1093\/brain\/124.11.2162","article-title":"Visual and motor evoked potentials in the course of multiple sclerosis","volume":"124","author":"Fuhr","year":"2001","journal-title":"Brain"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1191\/135248506ms1244oa","article-title":"Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis","volume":"12","author":"Kallmann","year":"2006","journal-title":"Mult. Scler."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2217\/cer-2020-0267","article-title":"Efficacy classification of modern therapies in multiple sclerosis","volume":"10","author":"Worthington","year":"2021","journal-title":"J. Comp. Eff. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult. Scler."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"105850","DOI":"10.1016\/j.msard.2024.105850","article-title":"Effects of disease-modifying therapies on remyelination in multiple sclerosis; evaluation via visual evoked potential test","volume":"91","author":"Saridas","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1167\/iovs.12-9843","article-title":"Axonal loss in a rat model of optic neuritis is closely correlated with visual evoked potential amplitudes using electroencephalogram-based scaling","volume":"53","author":"You","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3109\/01658107.2015.1074253","article-title":"Multifocal visual evoked potential (mfVEP) and pattern-reversal visual evoked potential changes in patients with visual pathway disorders: A case series","volume":"39","author":"Alshowaeir","year":"2015","journal-title":"Neuroophthalmology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","article-title":"Brain health: Time matters in multiple sclerosis","volume":"9","author":"Giovannoni","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1212\/NXI.0000000000000737","article-title":"Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study","volume":"7","author":"Tavazzi","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1474-4422(17)30278-8","article-title":"Retinal layer segmentation in multiple sclerosis: A systematic review and meta-analysis","volume":"16","author":"Petzold","year":"2017","journal-title":"Lancet Neurol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1750\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:10:49Z","timestamp":1789117849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medicina62091750"],"URL":"https:\/\/doi.org\/10.3390\/medicina62091750","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}